IRVINE, Calif., Sept. 16 /PRNewswire/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA TM ...
Please provide your email address to receive an email when new articles are posted on . IRVINE, Calif. — Ista Pharmaceuticals initiated a new phase 3 program designed to evaluate its proprietary ...
The Institute of Science and Technology Austria (ISTA) in Klosterneuburg announces a contribution of 750,000 Euros from an esteemed US philanthropist, aimed at financing the Institute’s translational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback